Safety in these pediatric populations was consistent with the known safety profile across approved adult and pediatric indications1,2
This facility will produce higher efficacy products that enjoy greater acceptance and enhanced profit marginsg
First and only PARP inhibitor to improve invasive disease-free survival in patients
Dr. Rizo brings extensive industry leadership experience to Vividion, having held multiple senior executive roles during her career at both biotechnology and large pharmaceutical companies.
ANI’s Clorazepate Dipotassium Tablets are the generic version of the Reference Listed Drug (RLD) Tranxene.
U.S. FDA has issued Form 483 with six observations after an inspection of the company’s formulation manufacturing facility based out of Baddi
Ex-Azithromycin has shown a growth of 8% and 14% in April 2022 and May 2022 respectively
Bringing next-gen cannabinoid therapeutics to cancer patients
The company is strategically expanding its product portfolio with a pipeline of new products that will form a strong foundation for future growth.
Both manufacturing facilities are based out of Benguluru, India
Subscribe To Our Newsletter & Stay Updated
